|
1
|
Koizumi W, Narahara H, Hara T, Takagane A,
Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama
W, et al: S-1 plus cisplatin versus S-1 alone for first-line
treatment of advanced gastric cancer (SPIRITS trial): A phase III
trial. Lancet Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tsuburaya A, Morita S, Kodera Y, Kobayashi
M, Shitara K, Yamaguchi K, Yoshikawa T, Yoshida K, Yoshino S and
Sakamoto J: A randomized phase II trial to elucidate the efficacy
of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as
a first-line treatment for advanced gastric cancer: XP
ascertainment vs. SP randomized PII trial (XParTS II). BMC Cancer.
12:3072012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yamada Y, Higuchi K, Nishikawa K, Gotoh M,
Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, et al:
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus
S-1 in chemotherapy-naïve patients with advanced gastric cancer.
Ann Oncol. 26:141–148. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maeda O, Ando T, Ohmiya N, Ishiguro K,
Watanabe O, Miyahara R, Hibi Y, Nagai T, Yamada K and Goto H:
Alteration of gene expression and DNA methylation in drug-resistant
gastric cancer. Oncol Rep. 31:1883–1890. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maeda O, Ando T, Ishiguro K, Watanabe O,
Miyahara R, Nakamura M, Funasaka K, Kazuhiro F, Ando Y and Goto H:
Safety of repeated cell-free and concentrated ascites reinfusion
therapy for malignant ascites from gastrointestinal cancer. Mol
Clin Oncol. 2:1103–1106. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Benjamini Y and Hochberg Y: Controlling
the false discovery rate: A practical and powerful approach to
multiple testing. J R Stat Soc B. 57:289–300. 1995.
|
|
7
|
Xu L, Corcoran RB, Welsh JW, Pennica D and
Levine AJ: WISP-1 is a Wnt-1- and beta-catenin-responsive oncogene.
Genes Dev. 14:585–595. 2000.PubMed/NCBI
|
|
8
|
Kyo S, Takakura M, Fujiwara T and Inoue M:
Understanding and exploiting hTERT promoter regulation for
diagnosis and treatment of human cancers. Cancer Sci. 99:1528–1538.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yasui W, Oue N, Ito R, Kuraoka K and
Nakayama H: Search for new biomarkers of gastric cancer through
serial analysis of gene expression and its clinical implications.
Cancer Sci. 95:385–392. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ko HL, Wang YS, Fong WL, Chi MS, Chi KH
and Kao SJ: Apolipoprotein C1 (APOC1) as a novel diagnostic and
prognostic biomarker for lung cancer: A marker phase I trial.
Thorac Cancer. 5:500–508. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu L, Yu XZ, Li TS, Song LX, Chen PL, Suo
TL, Li YH, Wang SD, Chen Y, Ren YM, et al: A novel protein tyrosine
kinase NOK that shares homology with platelet- derived growth
factor/fibroblast growth factor receptors induces tumorigenesis and
metastasis in nude mice. Cancer Res. 64:3491–3499. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kamino Y, Kurashige Y, Uehara O, Sato J,
Nishimura M, Yoshida K, Arakawa T, Nagayasu H, Saitoh M and Abiko
Y: HBD-2 is downregulated in oral carcinoma cells by DNA
hypermethylation, and increased expression of hBD-2 by DNA
demethylation and gene transfection inhibits cell proliferation and
invasion. Oncol Rep. 32:462–468. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li M, Zhang W, Zhang S, Wang C and Lin Y:
PART1 expression is associated with poor prognosis and tumor
recurrence in stage I–III non-small cell lung cancer. J Cancer.
8:1795–1800. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bulla R, Tripodo C, Rami D, Ling GS,
Agostinis C, Guarnotta C, Zorzet S, Durigutto P, Botto M and
Tedesco F: C1q acts in the tumour microenvironment as a
cancer-promoting factor independently of complement activation. Nat
Commun. 7:103462016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wen YG, Wang Q, Zhou CZ, Yan DW, Qiu GQ,
Yang C, Tang HM and Peng ZH: Identification and validation of
Kallikrein-ralated peptidase 11 as a novel prognostic marker of
gastric cancer based on immunohistochemistry. J Surg Oncol.
104:516–524. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Masugi Y, Nishihara R, Hamada T, Song M,
da Silva A, Kosumi K, Gu M, Shi Y, Li W, Liu L, et al: Tumor
PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to
Colorectal Cancer. Cancer Immunol Res. 5:1046–1055. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tan K, Kajino K, Momose S, Masaoka A,
Sasahara K, Shiomi K, Izumi H, Abe M, Ohtsuji N, Wang T, et al:
Mesothelin (MSLN) promoter is hypomethylated in malignant
mesothelioma, but its expression is not associated with methylation
status of the promoter. Hum Pathol. 41:1330–1338. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu Y, An S, Ward R, Yang Y, Guo XX, Li W
and Xu TR: G protein-coupled receptors as promising cancer targets.
Cancer Lett. 376:226–239. 2016. View Article : Google Scholar : PubMed/NCBI
|
